Compare AbbVie Inc (ABBV) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.9. The key difference: AbbVie Inc pays a 2.72% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | JNK | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Fixed Income |
52-Week High | $261.07 | $98.19 |
52-Week Low | $184.85 | $94.66 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
JNK trades at $96.15 with a slight 0.17% daily gain, but technical indicators show a bearish trend with 15 sell signals versus 1 buy. The ETF maintains consistent dividend distributions, with recent payouts around $0.52-$0.53. Market sentiment is cautious amid Federal Reserve uncertainty and inflation concerns, while bond ETF inflows hit record levels according to CNBC on June 25, 2026.
Outlook remains pressured by rising rate hike expectations and high-yield bond vulnerabilities. Risks include Fed policy shifts and economic volatility, but the ETF's yield appeal persists for income-focused investors. Analyst consensus is bearish, with Seeking Alpha rating JNK a SELL on June 15, 2026, citing exhausted tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
